Peripheral Blood Stem Cell Mobilization and Engraftment after Autologous Stem Cell Transplantation with Biosimilar rhG-CSF

Advances in Therapy

Volumn 31, Issue 4, 2014, Pages 451-460

  Reményi, Péter ^a   Gopcsa, László ^a   Marton, Imelda ^b   Réti, Marienn ^a   Mikala, Gábor ^a   Pető, Mónika ^a   Barta, Anikó ^a   Bátai, Árpád ^a   Farkas, Zita ^a   Borbényi, Zita ^b   Csukly, Zoltán ^a   Bodó, Imre ^a   Fábián, János ^a   Király, Ágnes ^a   Lengyel, Lilla ^a   Piukovics, Klára ^b   Torbágyi, Éva ^a   Masszi, Tamás ^a,c  

^a Szent Laszlo Hospital   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Autologous stem cell transplantation; Biosimilar rhG CSF; Engraftment; Hematology; Neutropenia; Oncology; Peripheral blood stem cell mobilization

Indexed keywords

ACICLOVIR; BIOSIMILAR AGENT; BORTEZOMIB; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FILGRASTIM; FLUCONAZOLE; HEMOGLOBIN; IFOSFAMIDE; LEVOFLOXACIN; MELPHALAN; PLERIXAFOR; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; HEMATOLOGIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CATHETER INFECTION; CELL DIFFERENTIATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; ENGRAFTMENT SYNDROME; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; HUNGARY; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPHIL; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PERIPHERAL BLOOD STEM CELL; PERIPHERAL T CELL LYMPHOMA; PNEUMONIA; RASH; RETROSPECTIVE STUDY; SEPSIS; SOFT TISSUE INFECTION; STEM CELL MOBILIZATION; THROMBOCYTE; THROMBOCYTE TRANSFUSION; WALDENSTROEM MACROGLOBULINEMIA; CHEMICALLY INDUCED; HEMATOLOGIC NEOPLASMS; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; FEMALE; FILGRASTIM; HEMATOLOGIC AGENTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; HUNGARY; MALE; MIDDLE AGED; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84939546657     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0114-z     Document Type: Article

References (12)

1. Gascon P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21:1419–29.
2. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol. 2012;7(Suppl 1):S29–34.
3. Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24:347–57.
4. Lefrère F, Brignier AC, Elie C, et al. First experience of autologous peripheral blood stem cell mobilisation with biosimilar granulocyte colony-stimulating factor. Adv Ther. 2011;28:304–10.
5. Ianotto JC, Tempescul A, Yan X, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant. 2012;47:874–6.
6. Publicover A, Richardson DS, Davies A, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol. 2013;162:107–11.
7. Oken, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:49–655.
8. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilisation of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059–64.
9. André M, Baudoux E, Bron D, et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilisation of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion. 2003;43:50–7.
10. Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilisation and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol. 2008;83:644–8.
11. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18:17–9.
12. Andreola G, Babic A, Rabascio C, et al. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. Eur J Haematol. 2012;88:154–8.